Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial

NCT06591273 is registered in ClinicalTrials.gov with Services Institute of Medical Sciences, Pakistan as lead sponsor.

NCT NCT06591273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06591273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
Lead sponsor
Services Institute of Medical Sciences, Pakistan
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 6, 2023
Completion date
November 5, 2024
Enrollment
104 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe chronic plaque psoriasis